Research programme: melanotransferrin conjugated therapeutics - biOasis/AstraZeneca
Latest Information Update: 06 May 2024
At a glance
- Originator MedImmune
- Developer AstraZeneca; biOasis Technologies
- Class Drug conjugates
- Mechanism of Action Biological transport stimulants; Transferrin-binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 20 Jun 2023 Discontinued - Preclinical for Neuropathic pain in Canada (Parenteral) before June 2023
- 28 Jun 2019 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (Parenteral, Injection)
- 12 May 2015 Preclinical trials in Neuropathic pain in Canada (Parenteral)